A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
April 15, 2024
End Date
September 17, 2028
Awarded By
Amgen, Inc.
Start Date
April 15, 2024
End Date
September 17, 2028